A2i Therapeutics
Novel Small-molecule Immuno-oncology Agents
Company Overview
Snapshot
Founded in November 2020, A2i Therapeutics operates with 1–10 employees. The company has secured funding across two rounds from two investors, including FutuRx and RMGP Biopharma Investment Fund. In November 2020, A2i Therapeutics was launched as a joint venture between FutuRx and Atomwise.
Business overview
A2i Therapeutics is focused on developing novel small-molecule immuno-oncology agents. The company leverages artificial intelligence for small-molecule drug discovery, specifically targeting a key protein involved in controlling the innate immune response and a potential immuno-oncology target. Operating within the Health Tech & Life Sciences sector, A2i Therapeutics serves the pharmaceutical industry, with a focus on oncology, drug discovery, immunology, and biotechnology.
Strategic signal
In December 2020, A2i Therapeutics was launched as a joint venture between FutuRx and Atomwise, funded by leading biopharma VCs and the Israeli Innovation Authority. This signals a strategic move to combine Atomwise's AI drug discovery platform with FutuRx's biotechnology incubation expertise, aiming to accelerate the development of novel immuno-oncology treatments. For investors, this highlights a strong foundational partnership and significant early-stage validation from both corporate and governmental funding sources in a high-growth therapeutic area.
Log in to access full profile ›Company Intelligence Q&A
- When was A2i Therapeutics founded?
- A2i Therapeutics was founded in November 2020.
- What is the primary focus of A2i Therapeutics?
- A2i Therapeutics is developing novel small-molecule immuno-oncology agents, utilizing artificial intelligence for drug discovery.
- Which entities launched A2i Therapeutics?
- A2i Therapeutics was launched in November 2020 as a joint venture between FutuRx and Atomwise.
- Which investors participated in A2i Therapeutics' funding rounds?
- A2i Therapeutics received funding from FutuRx and RMGP Biopharma Investment Fund in November 2020.
- Did A2i Therapeutics receive any grants?
- In November 2020, A2i Therapeutics secured a grant from the Israel Innovation Authority.